| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2883283 | The Annals of Thoracic Surgery | 2006 | 5 Pages |
Abstract
This study suggests that rFVIIa is safe and efficacious in the management of refractory postcardiotomy bleeding. The use of rFVIIa is associated with reduced blood loss, rapid improvement of coagulation variables, and decreased need for blood products. Further studies are necessary to determine the safety and efficacy of this new hemostatic agent and its precise role in the treatment of severe postoperative coagulopathy.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Farzan MD, Javier G. MD, Parwis B. MD, Corey MD, Gregory MD, David H. MD,